Filing Flows › BioXcel Therapeutics (BTAIQ) › Q1 2025
BioXcel Therapeutics (BTAIQ) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
BioXcel Therapeutics (BTAIQ) reported revenue of $168K for the first quarter 2025 (Q1 2025), -71% from a year earlier and -54% from the quarter before.
BioXcel Therapeutics, Q1 2025: revenue $168K (-71% year over year), net loss $7.3M, operating cash flow −$12.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $168K | -54% | -71% |
| Operating profit | −$10.1M | — | — |
| Net earnings | −$7.3M | — | — |
| Operating cash flow | −$12.0M | — | — |
What changed
Revenue was $168K in Q1 2025, down 71% year over year and down 54% from the previous quarter.
Operating costs exceeded revenue by $10.1M, an operating margin of -6011.3%. Total costs fell 59% while revenue fell 71%. The quarter ended with a net loss of $7.3M, narrower than the previous quarter's $10.9M loss. Non-operating items added $2.8M, -39% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$12.0M. Non-cash charges added back $76K of depreciation and $180K of share-based compensation. Working capital and other items used $5.0M.
Questions
What was BioXcel Therapeutics' revenue in the first quarter 2025?
BioXcel Therapeutics (BTAIQ) reported revenue of $168K for the first quarter 2025 (Q1 2025), -71% from a year earlier and -54% from the quarter before.